Clinical trial • Phase I • Infectious Disease
Clinical trial in Septic cholestasis
Phase I trial for Septic cholestasis. 48 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Septic cholestasis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 17-10-2024
- First CTIS Authorization Date
- 15-11-2024
Trial design
Phase I trial across 1 site in Germany.
- Target Sample Size
- 48
Recruitment
- Planned Sample Size
- 48
- Recruitment Window Months
- 11
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 48
Germany
- Earliest CTIS Part Ii Submission Date
- 29-10-2024
- Latest Decision Or Authorization Date
- 20-04-2026
- Processing Time Days
- 538
- Number Of Sites
- 1
- Number Of Participants
- 48
Sites
- Site Name
- Charite Research Organisation GmbH
- Contact Person Name
- András Maifeld
- Contact Person Email
- Andras.Maifeld@charite-research.org
Sponsor
Primary sponsor
- Full Name
- SmartDyeLivery GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Related trials
Other published trials that may interest you.
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis
- AMIKACIN SULFATE for Sepsis | Neutropenia
- LENACAPAVIR, ISLATRAVIR for HIV-1 infection
- piperacillin sodium, tazobactam sodium for Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae severe infection